SNP318 / SciNeuro Pharma, GSK - LARVOL DELTA

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: SciNeuro | Active, not recruiting ➔ Completed

Trial completion • Alzheimer's Disease • CNS Disorders

SciNeuro completes dosing in its Phase 1 clinical trial of SNP318, an oral therapeutic for Alzheimer's disease and other neurodegenerative diseases (PRNewswire) - P1 | N=82 | NCT05792163 | Sponsor: SciNeuro | "SciNeuro Pharmaceuticals...today announced the completion of dosing in its Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study....A Phase 2 study to assess clinical benefits of SNP318 in stratified AD patients is planned for 2024 as the next step to continue its global development....SNP318 was safe and well-tolerated with no serious adverse events (SAEs) observed. Pharmacokinetics and pharmacodynamics data revealed excellent oral exposure supporting for once-daily dosing. SNP318 has outstanding distribution in the cerebrospinal fluid (CSF) to achieve complete target inhibition in a clinical setting for both peripheral and CNS tissues."

New P2 trial • P1 data • Trial status • Alzheimer's Disease • CNS Disorders • Dementia

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease (clinicaltrials.gov) - P1 | N=86 | Active, not recruiting | Sponsor: SciNeuro | Recruiting ➔ Active, not recruiting

Enrollment closed • Alzheimer's Disease • CNS Disorders

SciNeuro Initiates Phase 1 Clinical Trial with SNP318, a Novel Lp-PLA2 Inhibitor Targeting Neurodegenerative and Inflammatory Diseases (PRNewswire) - "SciNeuro Pharmaceuticals today announced that SNP318, a novel Lp-PLA2 inhibitor, is advancing into Phase 1 clinical trials in Australia, positioning it for global development. SNP318 is a small molecule, optimized for CNS penetrance, to induce broader anti-inflammatory benefits. It has potential in the treatment of major neurodegenerative diseases where protection and restoration of vascular health are important....Initiation of the SNP318 Phase 1 program marks a significant milestone for SciNeuro, as a clinical stage company with a trajectory for the next phase of growth."

Trial status • CNS Disorders

A First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNP318 in Healthy Participants (clinicaltrials.gov) - P1 | N=86 | Recruiting | Sponsor: SciNeuro

New P1 trial